Merck KGaA (FRA:MRK) has been given a €98.00 ($116.67) target price by stock analysts at Morgan Stanley in a research note issued on Friday, December 1st. The firm currently has a “neutral” rating on the healthcare company’s stock. Morgan Stanley’s target price would indicate a potential upside of 9.19% from the stock’s current price.
A number of other analysts have also weighed in on the company. UBS Group set a €120.00 ($142.86) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Monday, October 23rd. Berenberg Bank set a €116.00 ($138.10) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, November 23rd. equinet set a €112.00 ($133.33) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, August 31st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Merck KGaA in a research note on Tuesday, November 28th. Finally, Societe Generale set a €103.00 ($122.62) price target on Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, September 5th. Twelve analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of €107.57 ($128.06).
Merck KGaA (MRK) traded down €1.02 ($1.21) during trading hours on Friday, hitting €89.75 ($106.85). The stock had a trading volume of 294,785 shares. The stock has a market capitalization of $11,600.00 and a price-to-earnings ratio of 21.02. Merck KGaA has a 52-week low of €87.33 ($103.96) and a 52-week high of €115.00 ($136.90).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.